Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors

British Journal of Dermatology

Volumn 165, Issue 3, 2011, Pages 465-473

  Tennis, P ^a   Gelfand, J M ^b   Rothman, K J ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; B CELL LYMPHOMA; BASAL CELL CARCINOMA; CANCER RISK; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC ERROR; DRUG SCREENING; DRUG USE; ECZEMA; HODGKIN DISEASE; HUMAN; MELANOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA;

ADMINISTRATION, TOPICAL; CALCINEURIN; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; LYMPHOMA; MELANOMA; RISK FACTORS; SKIN NEOPLASMS; TACROLIMUS;

EID: 80052261578     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10363.x     Document Type: Review

References (45)

1. Hanifin JM, Reed ML,. Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis 2007; 18: 82-91. (Pubitemid 47122151)
2. Levy RM, Gelfand JM, Yan AC,. The epidemiology of atopic dermatitis. Clin Dermatol 2003; 21: 109-15. (Pubitemid 36428981)
3. Williams HC, Grindlay DJ,. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin Exp Dermatol 2010; 35: 12-15.
4. Food and Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. 2006. Available at: (last accessed 15 May 2011).
5. Food and Drug Administration. Information for Healthcare Professionals: Pimecrolimus (marketed as Elidel). 2006. Available at: (last accessed 15 May 2011)
6. Food and Drug Administration. Information for Healthcare Professionals: Tacrolimus (marketed as Protopic). 2006. Available at: (last accessed 15 May 2011).
7. Ormerod AD,. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153: 701-5. (Pubitemid 41415894)
8. Maclure M,. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. Epidemiol Rev 1993; 15: 328-51.
9. Hanifin J, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl.): 44-7.
10. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131: 383-96. (Pubitemid 24290226)
11. Synnerstad I, Fredrikson M, Ternesten-Bratel A, Rosdahl I,. Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 1423-8.
12. Suissa S,. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16: 241-9. (Pubitemid 46431687)
13. Naylor M, Elmets C, Jaracz E, Rico JM,. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat 2005; 16: 149-53. (Pubitemid 41364773)
14. Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. J Eur Acad Dermatol Venereol 2008; 22: 195-203.
15. Luger TA, Gollnick H, Schwennesen T, et al. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis. J Dtsch Dermatol Ges 2007; 5: 908-14.
16. Schneeweiss S, Doherty M, Zhu S, et al. Topic treatments with pimecrolimus, tacrolimus, and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219: 7-21.
17. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111-16.
18. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother 2009; 43: 1956-63.
19. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419-28. (Pubitemid 38988028)
20. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778-83. (Pubitemid 32577862)
21. Grulich AE, Vajdic CM, Kaldor JM, et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 587-94. (Pubitemid 40723786)
22. Hagströmer L, Ye W, Nyrén O, Emtestam L,. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005; 141: 1123-7. (Pubitemid 41373958)
23. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16. (Pubitemid 46434650)
24. Becker N, Deeg E, Rüdiger T, Nieters A,. Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur J Cancer 2005; 41: 133-42. (Pubitemid 40029666)
25. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992; 3: 449-56.
26. Cartwright RA, McKinney PA, O'Brien C, et al. Non-Hodgkin's lymphoma: case-control epidemiological study in Yorkshire. Leuk Res 1988; 12: 81-8.
27. Fabbro-Peray P, Daures JP, Rossi JF,. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control 2001; 12: 201-12. (Pubitemid 32515367)
28. Söderberg KC, Hagmar L, Schwartzbaum J, Feychting M,. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004; 4: 51.
29. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case-control study. J Epidemiol Community Health 2000; 54: 431-6. (Pubitemid 30312519)
30. Bernstein L, Ross RK,. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992; 52 (19 Suppl.): S5510-15.
31. Cozen W, Cerhan JR, Martinez-Maza O, et al. The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin lymphoma risk. Cancer Causes Control 2007; 18: 821-31. (Pubitemid 47125113)
32. Lash TL, Fox MP, Fink AK,. Applying Quantitative Bias Analysis to Epidemiologic Data. 2009. Available at: (last accessed 15 May 2011).
33. Naleway AL, Belongia EA, Greenlee RT, et al. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med 2003; 139: 1-7.
34. Ming ME, Levy R, Hoffstad O, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol 2004; 50: 357-62. (Pubitemid 38316127)
35. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-76. (Pubitemid 43053551)
36. Bradford PT, Devesa SS, Anderson WF, Toro JR,. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-73.
37. Margolis DJ, Hoffstad O, Bilker W,. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-95. (Pubitemid 46659010)
38. Olesen AB, Engholm G, Storm HH, Thestrup-Pedersen K,. The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol 2005; 125: 445-9.
39. Yokota K, Gill TJ III, Shinozuka H,. Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis. Cancer Res 1989; 49: 4586-90. (Pubitemid 19208365)
40. Gschwendt M, Kittstein W, Marks F,. Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kd protein in mouse epidermis. Carcinogenesis 1987; 8: 203-7.
41. Tran C, Lübbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211: 341-7. (Pubitemid 41642109)
42. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-9. (Pubitemid 40489494)
43. van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat 2007; 18: 19-22. (Pubitemid 46410632)
44. Spieth K, Grundmann-Kollmann M, Runne U, et al. Mycosis-fungoides-type cutaneous T cell lymphoma of the hands and soles: a variant causing delay in diagnosis and adequate treatment of patients with palmoplantar eczema. Dermatology 2002; 205: 239-44. (Pubitemid 36158533)
45. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102: 2213-19. (Pubitemid 37122401)